Two-Drug immune attack shows promise against tough cancers

This study tested a combination of two immune-boosting drugs (eftilagimod alpha and pembrolizumab) in 187 people with advanced lung cancer or head/neck cancer that had not responded to prior treatments. The goal was to see if the combination could shrink tumors safely. Participants received the drugs by injection every two weeks, and doctors measured tumor changes using scans. The trial is completed, and results help determine if this approach improves outcomes for these hard-to-treat cancers.